Featured on MedicalXpress.com, researchers at UCLA have created a potentially promising new treatment for glioblastoma. The study, published in Neuro-Oncology, investigated the use of decitabine and genetically modified immune cells. The research team, led by Dr. Robert Prins and Dr. Linda Liau, focused on the impact this treatment combination could have on these types of aggressive brain tumors by building off previous research work in 2011. “In the new research, Prins and Liau used a technique called engineered adoptive T cell transfer, which involves extracting and growing immune cells outside of the body, then reprogramming them with the gene for a T cell receptor targeting New York esophageal squamous carcinoma, or NY-ESO-1. They are then injected back into mice with glioblastoma tumors to produce an immune response that targets the brain cancer.” The researchers administered decitabine prior to injecting the reprogrammed T cells due to the brain tumor cells inability to produce NY-ESO-1 naturally. The study results indicated that the procedure was about 50 percent effective. The researchers are hoping to verify these findings with further models.